For citations:
Nasonov E.L., Lisitsyna T.A., Zonova E.V., Kuzkina S.M. The effect of olokizumab on rheumatoid arthritis patient’s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1). Rheumatology Science and Practice. 2021;59(1):62-69. (In Russ.) https://doi.org/10.47360/1995-4484-2021-62-69
Email this article 